(BMSIC/DRUGS/15-05)

S.N.	Technical Eligibility Criteria as per NIT	***Name of Bidder : UNICURE INDIA LTD*** ***Corporate office:- C-677,new friends colony,*** ***New delhi-100025*** ***Works: C-21,22 &23 sector -3,Noaida 201301 Dist:- Gautambudhanagar(U.P)*** ***"Chart has been prepared on the basis of number of downloaded Pg. received (i.e.- 1-220) "***
1	Constitution of the Bidding Company/Firm such as Memorandum of Association and Article of Association with complete address. As per Clause 3(c).	Memorandum of Article and Association Submitted. (Pg-64-53) Company details-Name ,Addresss,Telephone No,E Mail and Fax No of Directors of the company as per annexure V submitted. (Pg-88). Certificate of incorporation also submitted.(Pg-63).
2	Power of Attorney or Resolution of Board by which the authorised signatory has been authorised by bidder firm to sign the documents. As per Clause 3 (e) of the NIT.	Self Attested copy of Resolution of Board with the name of Sri Puneet Sharma One of the Director of the Company submitted. (Pg No-52)
3	List of item Quoted in prescribed format as Annexure III as per Clause 3 (o)	List of quoted item(Products **NIT S.No-6,7,8,12,13,16,17,18,19,23,24,25,26,29,34,36,37,38,39,40,41,44,45,57,58,59,61,63,65,68,69,70,72,78,79,80,82,87,90,91,94,95,96,103,107,111,112,114,134,136,147,148,151,153,154,155,161,163,166,167,169,170,171,179,181,182,186,187,188,189,190,195,200,201 & 207.(75 Items Only)** submitted in Prescribed formet as Annexure III.(Pg-11-18)
4	• Minimum three years old valid manufacturing licence of the product quoted with latest license renewal certificate. As per clause 3(f). • Approved product list as per the license issued for quoted drugs for minimum three years. As per clause 3(f). • Manufacturing License along with approved product list must be valid till the last date of the submission of tender. As per clause 3(f). Bidders shall submit self attested copies of required manufacturing license and approved product list in support of above mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it. As per Clause 3(f)	**Copy Of Manufacturing Licence in Form-25 &28 Mfg No-03 of 1984 issued on 08.01.1984 & 03/SC/P OF 1984 issued date 08.01.1984 Submitted .** Renewal in Form -26 having **Mfg No. -03 of 1984 issued on 08.01.1984 & 03/SC/P OF 1984 issued date 08.01.1984 has been** renewed from 01.01.2012 to31.12.2016(Pg No- 141-143). Along With quoted product approval for Approval check list Enclosed.
5	In case of Importer, the bidder (importer) firm must have minimum three years old valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product are being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.As per Clause 3(g)	N/A
6	Self attested copies of Market standing certificate (in India) of minimum three years, issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. As per Clause 3(h)	Market Standing Certificate details Enclosed
7	Self attested copy of Non Conviction Certificate (NCC), issued by the concerned Licensing Authority from Drug Control Administration of the state for last three years. It should be not more than one year old. As per Clause 3(i).	Self attested copy of Non Conviction Certificate (NCC) issued by Drugs Licensing -Cum-ControllerAuthority (U.P) . Vide letter No 6115 dt 09.06.2015 stated as" Said Licensee not convicted during the proceding Five Year submitted.(Pg No-25)
8	Self attested copies of WHO-GMP/GMP as per revised Schedule-'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority / Drugs Control Department. The GMP certificate must not be older than one year form the last date of submission of tender. As per clause 3(j).	Self attested copies of GMP Certificate issued by Drugs Licensing -Cum- ControllerAuthority (U.P) . vide letter 3133 dt **06.06.2014** which is valid for one year **submitted.** **Same time Extension for six month of GMP and GLP vide letter no 6014 dt 05.06.2015 Submitted** (Pg- 148-149)
9	Self attested copies of Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority form Drugs Control Department highlighting the quoted product section. As per Clause 3(k).	Self attested copies of Maximum Production Capacity Certificate (section wise) per Annum(Tab-199.20 cr.Cap-21.84 Cr,liquid oral-172.800 lac,Cream-120 tons,Dry syrup 36 lac bottles,ointment 120 ton etc) issued by Drugs Licensing -Cum- ControllerAuthority (U.P) vide letter no-309 dt 15.01.2013 submitted(Pg no-19-20)
10	An affidavit sworn before first class magistrate/Notary stating that the firm & its quoted product is not black listed currently (as on the last date of submission of the tender) by Central Government/ Central Government Agencies/any state government/any of the state government agencies/any Drug Procurement Agencies or by BMSICL as per Annexure II (clause 3(n) of NIT).	Copy of affidavit sworn before Notary by authorized person stating that the **firm & its quoted product** is not black listed currently (as on the last date of submission of the tender) by Central Government/ Central Government Agencies/any state government/any of the state government agencies/any Drug Procurement Agencies or by BMSICL submitted.(Pg No22-24)
11	EMD details (DD number/BG number and date with issuing bank) as per Clause 3(b).	Rs. 5,00,000/- BG- AB9GPG 15-2470001, Canara Bank
12	Tender Fee Rs 10,000/- in form of DD as per Clause 3(a).	Rs. 10,000/-, DD No.- 501013, ICICI Bank
13	Self attested copies of the Audited Annual Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 crores for any three of the last four consecutive financial years. (Auditor/ C.A. Certificate of turnover will not be accepted). As per Clause 3(l)	F.Y.- 2011-12, P-152-151 Rs. 101.493 Crore F.Y. -2012-13 P-155-154 Rs. 135.024Crore F.Y. 2013-14 P-158-157 Rs. 32.54 Crore
14	Self attested copy of Income Tax Return for any three of last four consecutive Assessment years. As per Clause 3(m).	A.Y.- 2012-13 P- 144 A.Y.- 2013-14 P- 145 A.Y.- 2014-15 P- 146
15	Self attested copy of PAN Card of the Bidder Company. As per Clause 3(p)	P-21
16	Self attested copy of Certificate of valid Sales tax/VAT registration of the bidder company. As per Clause 3(q)	P-9-6
17	Affidavit declaration regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure IV (Clause 5(k) of NIT).	Copy of an affidavit sworn before Notary by authorized person on dt 31.08.2015 stating acceptance of tender conditions as per annexure IV. Submitted.(Pg-161)

The facts in clause No-1 to 10 and 17 of the provided sheet has been compiled with due deligence and care, on the basis of document provided by BMSICL, in compliance of letter No 515(15) Dt-21.08.2015 of Health Department, Govt of Bihar and letter no BMSIC/40010/2-2014/1678 Dt 18.09.2015 of GM (Supply Chain), BMSICL, Patna. Inspite, some inadvertent dicrepencies could have been crept in. Humble request to all concerned to bring to notice in due time, if any discrepencies is observed, for rectification.

UNICURE INDIA LTD.

PRODUCT LIST APPROVAL & MARKET STANDING STATUS

NIT S No	Product Approval Date(Pg No.)	Remarks	Market Standing(Pg No)	Remarks
6	20.03.2012(102)	Specification given in USP,where as NIT req is in I.P	Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(65)	
7	20.03.2012(129)		Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(65)	
8	20.03.2012(139)		Commissioner FDA,UP Vide letter no 3250 dated 01.04.2015(78)	
12	20.03.2012(138)		Commissioner FDA,UP Vide letter no 3250 dated 01.04.2015(80)	
13	20.03.2012(138)		Commissioner FDA,UP Vide letter no 252 dated 08.01.2015(67)	
16	20.03.2012(113)		Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(186)	
17	20.03.2012(113)		Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(186)	
18	20.03.2012(118)		Commissioner FDA,UP Vide letter no 3250 dated 01.04.2015(77)	
19	20.03.2012(111)		Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(186)	Pack size not mentioned in the approval & MSC
23	20.03.2012(129)	Specification given as polydimethylsiloxane where as NIT Req as Activated Dimethicone	Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(177)	Specification given as polydimethylsiloxane where as NIT Req as Activated Dimethicone
24	20.03.2012(138)		Commissioner FDA,UP Vide letter no 3250 dated 01.04.2015(73)	
25	20.03.2012(137)		Commissioner FDA,UP Vide letter no 252 dated 08.01.2015(71)	
26	20.03.2012(137)		Commissioner FDA,UP Vide letter no 3250 dated 01.04.2015(82)	
29	20.03.2012(112)		Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(186)	Pack size not mentioned in the approval & MSC
34	20.03.2012(136)	Specification given in USP,where as NIT req is in I.P	Commissioner FDA,UP Vide letter no 294dated 17.01.2014(162)	Specification given in USP,where as NIT req is in I.P
36	20.03.2012(116)		Not Submitted	Not Submitted
37	20.03.2012(104)	Claim given as 100mg/5 ml,Where as NIT req Per 20mg/ml	Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(184)	Specification in USP Wherein NIT Is in IP & Pack size not mentioned in the approval & MSC
38	20.03.2012(136)		Commissioner FDA,UP Vide letter no 3250 dated 01.04.2015(81)	
39	20.03.2012(128)	Specification given in USP,where as NIT req is in I.P	Commissioner FDA,UP Vide letter no 6118 dated 09.06.2015(90)	Specification given in USP,where as NIT req is in I.P
40	20.03.2012(111)		Commissioner FDA,UP Vide letter no 6987 dated 20.10.2014(167)	Pack size not mentioned in the approval & MSC

41	20.03.2012(118)		Commissioner FDA,UP Vide letter no 252 dated 08.01.2015(71)	
44	20.03.2012(118)	Speficication Given in USP & Dispersible tab,Where as NIT Req is I.P.	Commissioner FDA,UP Vide letter no 6118 dated 09.06.2015(89)	Speficication Given in USP & Dispersible tab,Where as NIT Req is I.P.
45	20.03.2012(121)	Specification given in USP,where as NIT req is in I.P	Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(183)	Specification given in USP,where as NIT req is in I.P
57	20.03.2012(117)		Commissioner FDA,UP Vide letter no 6118 dated 09.06.2015(89)	
58	20.03.2012(136)		Commissioner FDA,UP Vide letter no 252 dated 08.01.2015(70)	
59	20.03.2012(102)		Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(184)	Pack size not mentioned in the approval & MSC
61	20.03.2012(104)		Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(183)	Pack size not mentioned in the approval & MSC
63	20.03.2012(136)		Commissioner FDA,UP Vide letter no 3250 dated 01.04.2015(80)	
65	20.03.2012(135)		Commissioner FDA,UP Vide letter no 6987 dated 20.10.2014(168)	
68	20.03.2012(135)		Commissioner FDA,UP Vide letter no 6987 dated 20.10.2014(168)	
69	20.03.2012(127)		Commissioner FDA,UP Vide letter no 252 dated 08.01.2015(70)	
70	20.03.2012(127)		Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(183)	
72	20.03.2012(109)		Commissioner FDA,UP Vide letter no 3250 dated 01.04.2015(84)	NIT Requirement is Cresol IP 50%V/V Whereas in the approval & MSC Specification is 50% w/w
78	20.03.2012(134)		Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(183)	
79	20.03.2012(107)		Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(183)	
80	20.03.2012(134)	Given in Uncoated Where as in NIT Req is Gastro resistent Tab	Commissioner FDA,UP Vide letter no 252 dated 08.01.2015(69)	Given in Uncoated Where as in NIT Req is Gastro resistent Tab
82	20.03.2012(134)		Commissioner FDA,UP Vide letter no 6118 dated 09.06.2015(91)	
87	20.03.2012(114)		Commissioner FDA,UP Vide letter no 3250 dated 01.04.2015(84)	
90	Not Submitted		Commissioner FDA,UP Vide letter no 2570 dated 23.05.2014(165)	Specification is not as per NIT in MSC
91	20.03.2012(115)		Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(180)	
94	20.03.2012(133)		Commissioner FDA,UP Vide letter no 3250 dated 01.04.2015(82)	

95	20.03.2012(105)	Specification given in BP,where as NIT req is in I.P	Commissioner FDA,UP Vide letter no 6118 dated 09.06.2015(87)	Specification given in BP,where as NIT req is in I.P
96	20.03.2012(106)		Commissioner FDA,UP Vide letter no 3250 dated 01.04.2015(79)	
103	05.04.2013(96)		Not Submitted	
107	12.11.2012(97)		Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(169-170)	
111	20.03.2012(132)		Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(178-179)	
112	20.03.2012(132)		Commissioner FDA,UP Vide letter no 3250 dated 01.04.2015(83)	
114	20.03.2012(132)		Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(178)	
134	20.03.2012(131)		Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(176)	
136	20.03.2012(108)		Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(175)	
147	20.03.2012(120)		Commissioner FDA,UP Vide letter no 3250 dated 01.04.2015(77)	
148	20.03.2012(98)	Specification given for Ofloxacin With **Tinidazole** where as NIT Req Is **Ofloxacin** with Ornidazole	Not Submitted	
151	20.03.2012(99)	IP Overwrite	Commissioner FDA,UP Vide letter no 6118 dated 09.06.2015(86)	Pack size not mentioned in the approval & MSC
153	20.03.2012(101)		Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(174)	Pack size not mentioned in the approval & MSC
154	20.03.2012(126)		Commissioner FDA,UP Vide letter no 6118 dated 09.06.2015(76)	
155	20.03.2012(126)		Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(171)	
161	20.03.2012(100)		Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(171)	Pack size not mentioned in the approval & MSC
163	20.03.2012(103)		Commissioner FDA,UP Vide letter no 252 dated 08.01.2015(68)	Pack size not mentioned in the approval & MSC
166	20.03.2012(108)		Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(173)	
167	20.03.2012(108)		Commissioner FDA,UP Vide letter no 3250 dated 01.04.2015(80)	
169	20.03.2012(120)		Commissioner FDA,UP Vide letter no 3250 dated 01.04.2015(83)	
170	20.03.2012(120)		Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(173)	
171	20.03.2012(103)		Commissioner FDA,UP Vide letter no 3250 dated 01.04.2015(75)	

179	20.03.2012(125)		Commissioner FDA,UP Vide letter no 3250 dated 01.04.2015(81)	
181	20.03.2012(130)		Commissioner FDA,UP Vide letter no 3250 dated 01.04.2015(83)	
182	20.03.2012(130)		Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(170)	
186	20.03.2012(103)		Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(172)	
187	20.03.2012(124)	Specification in BP and gastro resistence where in NIT Req Is I.P and gastro resistent not mentioned	Commissioner FDA,UP Vide letter no 8787 dated 18.12.2014(172)	Specification in BP and gastro resistence where in NIT Req Is I.P and gastro resistent not mentioned
188	20.03.2012(130)	Specification in BP Where as NIT Req in I.P	Commissioner FDA,UP Vide letter no 3250 dated 1.4.2015(81)	Specification in BP Where as NIT Req in I.P
189	11.07.2013(95)		Not Submitted	3 yrs not completed
190	8.4.13(96)		Not Submitted	3 yrs not completed
195	20.03.2012(110)		Commissioner FDA,UP Vide letter no 2570 dated 23.05.2014(164)	Pack size not mentioned in the approval & MSC
200	20.03.2012(122)	Specification in BP Where as NIT Req in I.P	Commissioner FDA,UP Vide letter no 3250 dated 01.04.2015(73)	Approval for export only
201	Not Submitted		Not Submitted	
207	20.03.2012(119)		Commissioner FDA,UP Vide letter no 8902 dated 03.08.2015(93)